NAMSA Expands MedTech Portfolio in Market Intelligence and Customer Research Services through its Acquisition of EU-Based SUAZIO
NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced its acquisition of SUAZIO, an EU-based strategic consultancy providing global market research services to medical device and IVD developers.
Latest AI Insights : How AI Is Shaking up the Games Industry
“With similar values and experience in providing insights to accelerate MedTech innovation, our services are well-aligned to truly deliver global Clients end-to-end development and commercialization solutions that lead to success.”
Founded in 2001 in Antwerp, Belgium, SUAZIO’s mission is to provide market insights to the MedTech industry across the globe through its data, people and analytics solutions. The organization develops custom frameworks for each Client based on specific market needs, technology value drivers, patient journeys, digital healthcare environments and economic value propositions. Keeping each stakeholder’s perspective in mind, this research results in robust data and accurate interpretation leading to clear recommendations and strategies for successful market introductions.
“NAMSA is very enthusiastic to expand its global strategic consulting services with the addition of SUAZIO,” commented Dr. Christophe Berthoux, NAMSA CEO. “Client insights and precise market research are what power the true value of novel medical technologies and product acceptance. With the SUAZIO Team, NAMSA will expand its Client reach even further and strengthen the delivery of its full continuum development services to the global MedTech industry,” Dr. Berthoux concluded.
Read More AI : AI and Open Access Weather Data Will Provide Groundbreaking Insights
NAMSA’s other consulting services include Biological Safety, Quality, Regulatory, Reimbursement and Product Development Strategy. These teams are led by the MedTech industry’s foremost experts, many of whom have held positions with the U.S. Food and Drug Administration (FDA), EU Notified Bodies and APAC authorities. NAMSA Consultants, who communicate with global government entities daily, are uniquely qualified to provide wide-ranging consulting services across the product development spectrum. NAMSA’s proven services and outcomes ultimately allow Clients to get to market faster and make a more immediate impact on patient safety and global healthcare.
“SUAZIO has sought to extend its reach within the MedTech ecosystem for some time and we could not be more thrilled to join NAMSA in its mission to deliver best-in-class global MedTech solutions through our people, expertise and technology,” stated SUAZIO CEO, Christophe Van der Linden. “With similar values and experience in providing insights to accelerate MedTech innovation, our services are well-aligned to truly deliver global Clients end-to-end development and commercialization solutions that lead to success.”
Future Of AI : The Future of AI Is Here. Now Let’s Make It Ethical
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.